NCT01048892

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Children's Oncology Group · Network
• Sex: All
• Age: 3 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of Seneca Valley virus-001 in treating young patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features.

Detailed description

OBJECTIVES: Primary * To estimate the maximum-tolerated dose and/or recommended phase II dose of Seneca Valley virus-001 (NTX-010) when administered as a single infusion to pediatric patients with relapsed or refractory neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features (Wilms tumor, retinoblastoma, adrenocortical carcinoma, or carcinoid tumors). (Part A \[completed\]) * To confirm that there is viral replication in these patients following NTX-010 administration. (Part A \[completed\]) * To define and describe the toxicities of NTX-010 when administered on this schedule. (Part A \[completed\]) * To determine whether the number of regulatory T cells (as measured by flow cytometry) can effectively be reduced following administration of NTX-010 plus low-dose metronomic and intravenous cyclophosphamide. (Part B) * To characterize the pharmacokinetics (time course of viral clearance) following NTX-010 administration in these patients. Secondary * To preliminarily define the antitumor activity of NTX-010 within the confines of a phase I study. (Part A \[completed\]) * To evaluate the development of neutralizing antibodies to NTX-010 following IV administration of NTX-010. (Part A \[completed\]) * To evaluate development of neutralizing antibodies to NTX-010 following the combination of NTX-010 and cyclophosphamide. (Part B) * To investigate the presence and permissivity of occult circulating tumor cells prior to and after the initial intravenous administration of NTX-010. OUTLINE: This is a multicenter study. Part A (completed): Patients receive Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1. Part B: Patients receive cyclophosphamide IV orally (PO) on days 1-14 and NTX-010 IV over 1 hour on day 8. In the absence of disease progression or unacceptable toxicity, patients then receive cyclophosphamide orally (PO) on days 22-35, plus cyclophosphamide IV over 1 hour and NTX-010 IV over 1 hour on day 29. Tumor tissue samples are collected at baseline for biomarker studies. Blood and stool samples are collected periodically for neutralizing antibody and viral clearance studies. Additional blood samples may also be collected for the presence and permissivity of occult tumor cells. After completion of study treatment, patients are followed up periodically for up to 1 year.

Conditions

• Adrenocortical Carcinoma
• Gastrointestinal Carcinoid Tumor
• Kidney Cancer
• Neuroblastoma
• Retinoblastoma
• Sarcoma

Interventions

Type	Name	Description
BIOLOGICAL	Seneca Valley virus-001
DRUG	cyclophosphamide
OTHER	laboratory biomarker analysis
OTHER	pharmacological study

Timeline

• Start date: 2009-09-01
• Primary completion: 2013-06-01
• First posted: 2010-01-14
• Last updated: 2014-01-30

Locations

18 sites across 1 country: United States